Online citations, reference lists, and bibliographies.
← Back to Search

Antinociceptive Activity Of The Endogenous Fatty Acid Amide, Palmitylethanolamide.

A. Calignano, G. La Rana, D. Piomelli
Published 2001 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The endogenous fatty acid ethanolamide, palmitylethanolamide, alleviated, in a dose-dependent manner, pain behaviors elicited in mice by injections of formalin (5%, intraplantar), acetic acid (0.6%, 0.5 ml per animal, intraperitoneal, i.p.), kaolin (2.5 mg per animal, i.p.), and magnesium sulfate (120 mg per kg, i.p.). The antinociceptive effects of palmitylethanolamide were prevented by the cannabinoid CB2 receptor antagonist SR144528 [N-([1s]-endo-1.3.3-trimethylbicyclo[2.3.1]heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide], not by the cannabinoid CB1 receptor antagonist SR141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide x HCl]. By contrast, palmitylethanolamide had no effect on capsaicin-evoked pain behavior or thermal nociception. The endogenous cannabinoid, anandamide (arachidonylethanolamide), alleviated nociception in all tests (formalin, acetic acid, kaolin, magnesium sulfate, capsaicin and hot plate). These effects were prevented by the cannabinoid CB1 receptor antagonist SR141716A, not the cannabinoid CB2 receptor antagonist SR141716A. Additional fatty acid ethanolamides (oleylethanolamide, myristylethanolamide, palmitoleylethanolamide, palmitelaidylethanolamide) had little or no effect on formalin-evoked pain behavior, and were not investigated in other pain models. These results support the hypothesis that endogenous palmitylethanolamide participates in the intrinsic control of pain initiation. They also suggest that the putative receptor site activated by palmitylethanolamide may provide a novel target for peripherally acting analgesic drugs.
This paper references
10.1073/PNAS.96.25.14228
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
L. Hanuš (1999)
10.1038/7268
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
A. Giuffrida (1999)
10.1007/s002130050955
Local administration of Δ9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action
M.-C. Ko (1999)
Vanilloid (Capsaicin) receptors and mechanisms.
A. Szallasi (1999)
10.1073/PNAS.96.10.5780
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
A. Zimmer (1999)
10.1038/35012076
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
J. Davis (2000)
10.1126/SCIENCE.1470919
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
10.1016/0014-2999(96)00015-5
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
S. Mazzari (1996)
10.1006/ABIO.2000.4509
Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry.
A. Giuffrida (2000)
10.1523/JNEUROSCI.16-12-03934.1996
Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and its Control by Calcium and cAMP
H. Cadas (1996)
10.1038/39807
The capsaicin receptor: a heat-activated ion channel in the pain pathway
M. Caterina (1997)
10.1016/S0024-3205(99)00289-1
The neurobiology of cannabinoid analgesia.
J. M. Walker (1999)
10.1016/S0304-3959(98)00041-4
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
S. Jaggar (1998)
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.
G. Griffin (2000)
10.1016/S0165-6147(00)01482-6
The endocannabinoid system as a target for therapeutic drugs.
D. Piomelli (2000)
10.1016/0014-5793(94)00773-X
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
M. Rinaldi-Carmona (1994)
10.1074/JBC.270.11.6030
Anandamide Amidohydrolase Activity in Rat Brain Microsomes
F. Desarnaud (1995)
10.1126/SCIENCE.277.5329.1094
Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
M. Beltramo (1997)
10.1016/S0306-4522(98)00524-7
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study
A. Hohmann (1999)
10.1523/JNEUROSCI.17-04-01226.1997
Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain
H. Cadas (1997)
10.1016/S0079-6123(00)29034-1
A role for the endogenous cannabinoid system in the peripheral control of pain initiation.
A. Calignano (2000)
10.1016/S0306-4522(00)00389-4
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
J. Ahluwalia (2000)
10.1038/382677A0
Brain cannabinoids in chocolate
E. Tomaso (1996)
10.1073/PNAS.96.10.5802
Structural determinants for recognition and translocation by the anandamide transporter.
D. Piomelli (1999)
10.1038/372686A0
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
V. Marzo (1994)
10.1016/S0014-2999(00)00226-0
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.
P. Beaulieu1 (2000)
10.1016/S0304-3959(97)00213-3
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
J. D. Richardson (1998)
10.1073/PNAS.92.8.3376
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
L. Facci (1995)
10.1016/s0021-9258(18)97531-9
FATTY ACID AMIDES OF ETHANOLAMINE IN MAMMALIAN TISSUES.
N. Bachur (1965)
10.1152/PHYSREV.1987.67.1.67
Peripheral and spinal mechanisms of nociception.
J. Besson (1987)
10.1038/365061A0
Molecular characterization of a peripheral receptor for cannabinoids
S. Munro (1993)
10.1038/28393
Control of pain initiation by endogenous cannabinoids
A. Calignano (1998)



This paper is referenced by
10.1186/s12974-018-1126-4
HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia
G. Sarnelli (2018)
10.1016/j.neuropharm.2005.01.001
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies
N. Darmani (2005)
10.3109/14756366.2011.643304
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide
C. Fowler (2013)
10.1016/J.LFS.2005.12.028
Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat.
E. Murillo-Rodríguez (2006)
10.1002/cmdc.201300546
3‐Aminoazetidin‐2‐one Derivatives as N‐Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration
A. Fiasella (2014)
10.1016/j.phrs.2010.03.007
Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
J. Spradley (2010)
10.1016/S0028-3908(02)00040-0
The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats
H. C. Ellington (2002)
10.1213/ANE.0b013e3182707859
CB1 and CB2 Cannabinoid Receptor Agonists Induce Peripheral Antinociception by Activation of the Endogenous Noradrenergic System
T. Romero (2013)
10.1124/jpet.111.191403
The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models
A. Caprioli (2012)
10.4172/2155-9562.1000304
From the Ancient Diets to the Recent Acquisitions on the Role of Brain Inflammation in Epilepsy, Are there Any Links?
P. Mainardi (2015)
10.1021/jm900051r
Galactosyl prodrug of ketorolac: synthesis, stability, and pharmacological and pharmacokinetic evaluations.
A. Curcio (2009)
10.1007/s11062-005-0073-8
Pre- and Post-Synaptically Induced Short-Term Plasticity of GABA-ergic Synaptic Transmission
M. Storozhuk (2005)
PAIN When does acute pain become chronic ?
C. Voscopoulos (2010)
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Bekir B. Artukoglu (2017)
10.1111/j.1365-2710.2010.01190.x
Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example
R. B. Raffa (2011)
10.1111/j.1582-4934.2011.01267.x
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide
C. Scuderi (2011)
10.1007/978-0-387-74349-3_4
Other Cannabimimetic Lipid Signaling Molecules
H. Bradshaw (2008)
10.1111/j.1365-2826.2008.01689.x
A Saturated N‐Acylethanolamine Other than N‐Palmitoyl Ethanolamine with Anti‐inflammatory Properties: a Neglected Story…
M. Dalle Carbonare (2008)
10.1021/pr200735a
Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase.
Jay M West (2012)
10.1159/000087361
Endogenous Cannabinoid Receptor Agonists Inhibit Neurogenic Inflammations in Guinea Pig Airways
S. Yoshihara (2005)
Tratamiento farmacológico de la obesidad: presente, pasado y futuro
L. Valdelamar (2007)
10.1016/j.phrs.2013.07.007
N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.
G. Mattace Raso (2013)
10.1021/jm300484d
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
Y. Avraham (2013)
10.1038/sj.bjp.0706093
The expanding field of cannabimimetic and related lipid mediators
H. Bradshaw (2005)
10.2174/092986710790980014
From surface to nuclear receptors: the endocannabinoid family extends its assets.
M. Pistis (2010)
10.1007/s10787-013-0191-7
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain
S. Skaper (2013)
10.1016/j.lfs.2012.09.024
N-(4-Methoxy-2-nitrophenyl)hexadecanamide, a palmitoylethanolamide analogue, reduces formalin-induced nociception.
J. Roa-Coria (2012)
UNIVERSIDADE DE SÃO PAULO INSTITUTO DE QUÍMICA DE SÃO CARLOS Estudo da modelagem molecular do receptor canabinoide CB1 e suas interações com o Δ 9 - THC
Emmanuela Ferreira de Lima (2009)
Antinociceptive effects and mechanisms of action of Clinacanthus nutans Lindau leaf methanolic and petroleum ether extracts in mice
A. Rahim (2017)
10.1007/s00702-014-1255-6
Intracisternal injection of palmitoylethanolamide inhibits the peripheral nociceptive evoked responses of dorsal horn wide dynamic range neurons
A. González-Hernández (2014)
10.1039/C5MD00333D
Ligand-based homology modelling of the human CB2 receptor SR144528 antagonist binding site: a computational approach to explore the 1,5-diaryl pyrazole scaffold
E. Cichero (2015)
10.1159/000098702
Endogenous Phospholipid Metabolite Containing Topical Product Inhibits Ultraviolet Light-Induced Inflammation and DNA Damage in Human Skin
L. Kemény (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar